AC Immune (FRA:IMR) Total Liabilities : €121.33 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Total Liabilities?

AC Immune's Total Liabilities for the quarter that ended in Sep. 2024 was €121.33 Mil.

AC Immune's quarterly Total Liabilities increased from Mar. 2024 (€23.40 Mil) to Jun. 2024 (€118.60 Mil) and increased from Jun. 2024 (€118.60 Mil) to Sep. 2024 (€121.33 Mil).

AC Immune's annual Total Liabilities declined from Dec. 2021 (€28.31 Mil) to Dec. 2022 (€17.17 Mil) but then increased from Dec. 2022 (€17.17 Mil) to Dec. 2023 (€23.51 Mil).

AC Immune Total Liabilities Historical Data

The historical data trend for AC Immune's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Total Liabilities Chart

AC Immune Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

24.55

21.52

28.31

17.17

23.51

AC Immune Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															18.04	23.51	23.40	118.60	121.33

AC Immune Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AC Immune's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.395	+	(2.996	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	6.118)
	=	23.51

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	193.849	-	170.34
	=	23.51

AC Immune's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	107.4	+	(2.541	+	-3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.094	+	6.293)
	=	121.33

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	259.759	-	138.431
	=	121.33

AC Immune Total Liabilities Related Terms

Thank you for viewing the detailed overview of AC Immune's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AC Immune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (FRA:IMR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ACIU:USA IMR:Germany

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune Headlines

No Headlines